MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Fundamental Analysis
TSX:MDP - CA58410Q2036 - Common Stock
3.05 CAD
-0.06 (-1.93%)
We assign a fundamental rating of 5 out of 10 to MDP. MDP was compared to 35 industry peers in the Pharmaceuticals industry. MDP has only an average score on both its financial health and profitability. A decent growth rate in combination with a cheap valuation! Better keep an eye on MDP.
1. Profitability
1.1 Basic Checks
MDP had positive earnings in the past year.
MDP had a positive operating cash flow in the past year.
In multiple years MDP reported negative net income over the last 5 years.
In multiple years MDP reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.52%, MDP is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
With a decent Return On Equity value of 1.52%, MDP is doing good in the industry, outperforming 80.00% of the companies in the same industry.
The Return On Invested Capital of MDP (8.11%) is better than 91.43% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MDP is above the industry average of 7.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.52% | ||
| ROE | 1.52% | ||
| ROIC | 8.11% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
The Profit Margin of MDP (0.76%) is better than 71.43% of its industry peers.
MDP has a better Operating Margin (7.99%) than 80.00% of its industry peers.
MDP has a Gross Margin of 52.55%. This is amongst the best in the industry. MDP outperforms 82.86% of its industry peers.
In the last couple of years the Gross Margin of MDP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.99% | ||
| PM (TTM) | 0.76% | ||
| GM | 52.55% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. Health
2.1 Basic Checks
MDP has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, MDP has more shares outstanding
MDP has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MDP has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.62, we must say that MDP is in the distress zone and has some risk of bankruptcy.
MDP has a Altman-Z score of 0.62. This is in the better half of the industry: MDP outperforms 65.71% of its industry peers.
The Debt to FCF ratio of MDP is 1.29, which is an excellent value as it means it would take MDP, only 1.29 years of fcf income to pay off all of its debts.
MDP's Debt to FCF ratio of 1.29 is amongst the best of the industry. MDP outperforms 94.29% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that MDP is not too dependend on debt financing.
The Debt to Equity ratio of MDP (0.00) is better than 88.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.29 | ||
| Altman-Z | 0.62 |
ROIC/WACC0.82
WACC9.94%
2.3 Liquidity
A Current Ratio of 0.81 indicates that MDP may have some problems paying its short term obligations.
MDP's Current ratio of 0.81 is on the low side compared to the rest of the industry. MDP is outperformed by 88.57% of its industry peers.
A Quick Ratio of 0.37 indicates that MDP may have some problems paying its short term obligations.
MDP has a worse Quick ratio (0.37) than 85.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.37 |
3. Growth
3.1 Past
The earnings per share for MDP have decreased strongly by -50.00% in the last year.
The Revenue has decreased by -2.87% in the past year.
The Revenue has been growing slightly by 7.82% on average over the past years.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
Revenue 1Y (TTM)-2.87%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-9.78%
3.2 Future
Based on estimates for the next years, MDP will show a very strong growth in Earnings Per Share. The EPS will grow by 53.29% on average per year.
Based on estimates for the next years, MDP will show a quite strong growth in Revenue. The Revenue will grow by 10.09% on average per year.
EPS Next Y-175.75%
EPS Next 2Y90.52%
EPS Next 3Y104.09%
EPS Next 5Y53.29%
Revenue Next Year-5.4%
Revenue Next 2Y4.85%
Revenue Next 3Y8.33%
Revenue Next 5Y10.09%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 101.67, which means the current valuation is very expensive for MDP.
Based on the Price/Earnings ratio, MDP is valued a bit cheaper than the industry average as 77.14% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.13. MDP is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 7.64, the valuation of MDP can be described as very cheap.
88.57% of the companies in the same industry are more expensive than MDP, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.76, MDP is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 101.67 | ||
| Fwd PE | 7.64 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MDP is valued cheaply inside the industry as 97.14% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, MDP is valued cheaper than 91.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.22 | ||
| EV/EBITDA | 5.06 |
4.3 Compensation for Growth
MDP has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MDP's earnings are expected to grow with 104.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y90.52%
EPS Next 3Y104.09%
5. Dividend
5.1 Amount
No dividends for MDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MDP (8/29/2025, 7:00:00 PM)
3.05
-0.06 (-1.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners2.98%
Inst Owner ChangeN/A
Ins Owners7.25%
Ins Owner ChangeN/A
Market Cap98.39M
Analysts80
Price Target6.3 (106.56%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)101.23%
Min EPS beat(2)58.46%
Max EPS beat(2)144%
EPS beat(4)3
Avg EPS beat(4)43.05%
Min EPS beat(4)-100%
Max EPS beat(4)144%
EPS beat(8)5
Avg EPS beat(8)4.43%
EPS beat(12)9
Avg EPS beat(12)92.45%
EPS beat(16)10
Avg EPS beat(16)67.52%
Revenue beat(2)0
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-0.63%
Max Revenue beat(2)-0.44%
Revenue beat(4)1
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-0.63%
Max Revenue beat(4)6.82%
Revenue beat(8)2
Avg Revenue beat(8)-2.13%
Revenue beat(12)5
Avg Revenue beat(12)0.19%
Revenue beat(16)8
Avg Revenue beat(16)1.71%
PT rev (1m)-4.42%
PT rev (3m)0.93%
EPS NQ rev (1m)78.26%
EPS NQ rev (3m)-127.27%
EPS NY rev (1m)37.5%
EPS NY rev (3m)37.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.62%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)1.25%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 101.67 | ||
| Fwd PE | 7.64 | ||
| P/S | 0.68 | ||
| P/FCF | 4.22 | ||
| P/OCF | 3.62 | ||
| P/B | 1.35 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.06 |
EPS(TTM)0.03
EY0.98%
EPS(NY)0.4
Fwd EY13.09%
FCF(TTM)0.72
FCFY23.67%
OCF(TTM)0.84
OCFY27.61%
SpS4.5
BVpS2.26
TBVpS-1.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.52% | ||
| ROE | 1.52% | ||
| ROCE | 11.27% | ||
| ROIC | 8.11% | ||
| ROICexc | 9.27% | ||
| ROICexgc | N/A | ||
| OM | 7.99% | ||
| PM (TTM) | 0.76% | ||
| GM | 52.55% | ||
| FCFM | 16.03% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.29 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 34.4% | ||
| Cap/Sales | 2.67% | ||
| Interest Coverage | 2.18 | ||
| Cash Conversion | 118.79% | ||
| Profit Quality | 2101.86% | ||
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.37 | ||
| Altman-Z | 0.62 |
F-Score5
WACC9.94%
ROIC/WACC0.82
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
EPS Next Y-175.75%
EPS Next 2Y90.52%
EPS Next 3Y104.09%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-2.87%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-9.78%
Revenue Next Year-5.4%
Revenue Next 2Y4.85%
Revenue Next 3Y8.33%
Revenue Next 5Y10.09%
EBIT growth 1Y-31.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.11%
EBIT Next 3Y60.67%
EBIT Next 5Y50.41%
FCF growth 1Y164.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y191.19%
OCF growth 3YN/A
OCF growth 5YN/A